Author: OurCrowd

[DailyPay in PR NewsWire] Retail employees with DailyPay pay fewer late fees, use payday loans less, and incur less credit card debt according to new study from Arizent/Employee Benefits News

Nov 1, 2023 |

NEW YORK, Nov. 1, 2023 /PRNewswire/ — Retail workers are able to avoid such financially crippling fees associated with payday loans and late penalties, while amassing less credit card debt when they have access to the financial wellness benefit of DailyPay, according to new research from Arizent/Employee Benefits News. Read...

Read More

[Appdome in Forbes] Appdome CEO Tom Tovar talks his company’s mission, android accessibility service attacks, more in interview

Nov 1, 2023 |

In a press release issued in late September, Bay Area-based mobile security company Appdome announced so-called “new mobile anti-malware protections” which detect various kinds of Android Accessibility Service malware. According to Appdome, malware of this type is oftentimes used to “carry out large scale, distributed attacks on mobile banking apps, crypto wallets, and other financial services apps.” Read...

Read More

[Polarisqb in EIN Newswires] Quantum-aided drug design from POLARISqb demonstrates best-in-class capabilities

Nov 1, 2023 |

DURHAM, NC, USA, November 1, 2023 /EINPresswire.com/ — Polaris Quantum Biotech (POLARISqb), the leader in quantum computing-based drug design, announced the development of Quantum-Aided Drug Design (QuADD) for molecular library optimization in April 2023. QuADD runs on quantum computers that solve problems with unprecedented speed and power, allowing users to search a chemical space of more than 10^30 molecules for those that complement their specific binding pocket. This Software-as-a-Service platform builds custom, enriched molecular libraries, and it is currently available to customers. As a part of a series of white papers detailing how QuADD works, POLARISqb released a white paper concerning Best-in-Class mode. This new feature identifies novel molecules that are just outside the published intellectual property of a given template ligand. Read more...

Read More